AustinPx Invests in Pharmaceutics and Manufacturing Capabilities to Accelerate Drug Development
The latest investments enhance AustinPx’s early phase development and manufacturing capabilities by enabling faster timelines, improved stability, and reduced risk.
- The latest investments enhance AustinPx’s early phase development and manufacturing capabilities by enabling faster timelines, improved stability, and reduced risk.
- The technology enables rapid transition into first-in-human clinical trial material manufacturing, while also reducing the cost of drug product development.
- “These tools enable scientists and engineers to rapidly develop life-changing therapies with enhanced data and quality.”
The expanded capabilities are now available for use. - The additional capabilities mark another milestone in the growth of AustinPx’s formulation development and manufacturing offerings, as the Company continues to position itself as a leading CDMO in the pharmaceutical industry.